希望大家可以幫吓可仁啦😢 我希望個個小朋友都可以健康快樂咁成長,可以一齊去公園玩
【最新消息:募捐行動已於2018年12月3日結束】中大校友慈善基金感謝各界慷慨支持,募捐行動已結束。所得善款將支持張可仁及患上相類疾病需免疫治療的其他6位病童。
詳情請參閱中大校友慈善基金網頁:https://www.facebook.com/cuhkacf.org/posts/589827338133781
-------------------------------------------------------------------------------------
(2018/11/22)
中大醫學院向大家作出緊急呼籲,支持我們2000年的醫科畢業生張俊傑醫生,拯救他只有17個月大的兒子張可仁的性命。
可仁早於出生第4天時已被診斷罹患一種罕有心臟病「主動脈狹窄」(Coarctation of Aorta),需要接受緊急手術。極之不幸的是,可仁最近再被確診患上「第四期神經母腫瘤」(Stage IV Neuroblastoma),目前可仁的頭骨至腰椎和盆骨均受到癌細胞擴散,脊髓神經線受到癌細胞壓住,痛楚非常,並有癱瘓的危機,癌細胞更正轉移至骨髓。
可仁現時正住在威爾斯親王醫院兒童癌症中心隔離病房,極容易受到感染。他已開始接受化療,而治療方案將包括化療、手術、放射治療、骨髓移植、免疫治療,治療時間約一年至一年半。他完成化療、手術和放射治療後,會進行骨髓移植,之後需要免疫療法,這可大大提高存活率,由20%升至50%。
然而,免疫治療需要病人自費,所需費用高達港幣200萬元。張醫生另一兒子患有自閉症,太太辭掉小學主任一職,全職照顧兩位小朋友,並要照顧父母親,經濟上未能承擔高昂的醫療費用。
中大醫學院2000年畢業同學會發起是次籌款,目的包括:
1. 為可仁進行骨髓移植後的免疫治療;
2. 引發社會人士及政府對兒童罕有癌症治療的關注。
查詢:
香港中文大學校友慈善基金
電郵:info@cuhkacf.org
電話:2180 4316
-------------------------------------------------------------------------------------
【Fundraising Campaign Completed on 3 December 2018】According to CUHK Alumni Charity Foundation, the fundraising campaign for Mark CHEUNG Ho Yan has completed. The fund raised will be used to support the immunotherapy of Mark and 6 other patients who are suffered from the same disease. Thank you for all your kind-hearted support and generosity.
-------------------------------------------------------------------------------------
(2018/11/22)
This is an urgent appeal for your generosity to save the life of the 17-month-old son of Dr. CHEUNG Chun Kit, our medical alumnus of Class 2000.
Dr. Cheung Chun Kit is a CUHK medical graduate of Year 2000. His younger son, Cheung Ho Yan Mark, has recently been diagnosed to have Stage IV Neuroblastoma in November 2018, and is in an emergency need of donation to provide the necessary funding to support the life-saving yet expensive immunotherapy.
Mark was presented to his paediatrician for fever and cough in late October 2018. His cough resolved with treatment but his fever never completely went away. Two days prior to his diagnosis, Mark was more clingy than usual and did not like to walk. On a video clip, Mark was noted to have foot drop, a very significant red flag which may indicate a compression on the spinal cord. Emergency scans were immediately performed that night, and Mark was found to have a large tumour on the left side of his abdomen. The aggressive tumour had already spread silently to the back of his skull, his spine, his hips and had compressed his nerves which control his lower limbs, resulting in pain on standing and difficulty in walking. Mark is facing an imminent risk of paralysis.
Mark is diagnosed to have a rare childhood cancer which is called Stage IV neuroblastoma, a cancer which typically presents at late stage because it arises deep in the abdomen. To cure his aggressive cancer, Mark needs to survive through rounds of intensive chemotherapy, radiotherapy, surgery, bone marrow transplant, and finally, immunotherapy. The whole treatment duration lasts 1.5 to 2 years. To completely eradicate all cancer cells, immunotherapy will be needed to boost Mark’s survival from 20% to 50%. However, immunotherapy is a self-financed treatment in the public hospital and the treatment costs could be up to 2 million.
Such close encounter with death is not the first time for Mark. At the first week of life, Mark was diagnosed to have a rare heart problem called “Coarctation of Aorta”. Mark had received life-saving surgery to reestablish the blood flow across his aorta, the major blood vessel that allows blood to go from the heart to the brain and the rest of the body. In a report published in 2002, only 67 cases with dual heart condition and neuroblastoma were reported, giving an odd of 1 in 100 million for a child to be hit by these two rare diseases. Scientists have not yet completely understood the mechanisms that may cause the two conditions to appear in a single child.
It never rains but pours that Mark’s elder brother, now 5 years old, was diagnosed to have autism at around age 2. To enable the elder brother to have intensive training to improve his outcome and development, Mark’s mommy quit her job as a primary school teacher since the diagnosis of autism was made for his elder brother. Dr. Cheung, who is a medical doctor for the elderly, became the sole bread-winner of his family.
CUHK Medical Graduates of Year 2000 have initiated a fund-raising campaign for Mark and his family with the following two objectives:
1. To appeal for donation to support the costs of immunotherapy for Mark
2. To increase the public awareness on the grave needs of children with cancers
Enquiries:
CUHK Alumni Charity Foundation Limited
Email: info@cuhkacf.org
Telephone: 2180 4316
「神經母細胞瘤第四期存活率」的推薦目錄:
- 關於神經母細胞瘤第四期存活率 在 赤米 Nereus Facebook 的精選貼文
- 關於神經母細胞瘤第四期存活率 在 關你蛋事 Facebook 的最佳貼文
- 關於神經母細胞瘤第四期存活率 在 Queenie Chan 莉敏 Facebook 的最佳解答
- 關於神經母細胞瘤第四期存活率 在 社團法人台灣神經母細胞瘤病友關懷協會 - Facebook 的評價
- 關於神經母細胞瘤第四期存活率 在 治療神經母細胞瘤新曙光! 可減緩腫瘤擴散-民視新聞 - YouTube 的評價
- 關於神經母細胞瘤第四期存活率 在 神經母細胞瘤2023-在Facebook/IG/Youtube上的焦點新聞和 ... 的評價
- 關於神經母細胞瘤第四期存活率 在 神經母細胞瘤2023-在Facebook/IG/Youtube上的焦點新聞和 ... 的評價
神經母細胞瘤第四期存活率 在 關你蛋事 Facebook 的最佳貼文
【中大醫學院罕有網上募捐】
中文大學醫學院剛於Facebook專頁發出緊急呼籲,指學院一名醫科畢業生,其年僅17個月大的兒子確診患上罕見病「第四期神經母腫瘤」,而癌細胞已擴散至頭骨、腰椎和盆骨等部分。
由於該名病童須接受化療及相關治療,並以免疫療法提高存活率,但所需費用高達200萬元,而該名醫科畢業生的家庭內仍有另一名患有自閉症兒子,經濟上難以負擔高昂費用,故他同屆的畢業同學會發起是次籌款。
愛心爆棚既香港人係時候出動啦!詳情可睇返 https://www.facebook.com/CUHKMedicine/
關你蛋事IG:@hongkong88news
https://www.instagram.com/hongkong88news
#中大 #醫學院 #BB #罕見病 #化療 #慘慘 #眾籌 #醫生爸
#關你蛋事 #like4like #follow4follow #f4f #instafollow #hk #hkig #hongkong #hongkong88news #news
神經母細胞瘤第四期存活率 在 Queenie Chan 莉敏 Facebook 的最佳解答
🙏🏻🙏🏻🙏🏻
【最新消息:募捐行動已於2018年12月3日結束】中大校友慈善基金感謝各界慷慨支持,募捐行動已結束。所得善款將支持張可仁及患上相類疾病需免疫治療的其他6位病童。
詳情請參閱中大校友慈善基金網頁:https://www.facebook.com/cuhkacf.org/posts/589827338133781
-------------------------------------------------------------------------------------
(2018/11/22)
中大醫學院向大家作出緊急呼籲,支持我們2000年的醫科畢業生張俊傑醫生,拯救他只有17個月大的兒子張可仁的性命。
可仁早於出生第4天時已被診斷罹患一種罕有心臟病「主動脈狹窄」(Coarctation of Aorta),需要接受緊急手術。極之不幸的是,可仁最近再被確診患上「第四期神經母腫瘤」(Stage IV Neuroblastoma),目前可仁的頭骨至腰椎和盆骨均受到癌細胞擴散,脊髓神經線受到癌細胞壓住,痛楚非常,並有癱瘓的危機,癌細胞更正轉移至骨髓。
可仁現時正住在威爾斯親王醫院兒童癌症中心隔離病房,極容易受到感染。他已開始接受化療,而治療方案將包括化療、手術、放射治療、骨髓移植、免疫治療,治療時間約一年至一年半。他完成化療、手術和放射治療後,會進行骨髓移植,之後需要免疫療法,這可大大提高存活率,由20%升至50%。
然而,免疫治療需要病人自費,所需費用高達港幣200萬元。張醫生另一兒子患有自閉症,太太辭掉小學主任一職,全職照顧兩位小朋友,並要照顧父母親,經濟上未能承擔高昂的醫療費用。
中大醫學院2000年畢業同學會發起是次籌款,目的包括:
1. 為可仁進行骨髓移植後的免疫治療;
2. 引發社會人士及政府對兒童罕有癌症治療的關注。
查詢:
香港中文大學校友慈善基金
電郵:info@cuhkacf.org
電話:2180 4316
-------------------------------------------------------------------------------------
【Fundraising Campaign Completed on 3 December 2018】According to CUHK Alumni Charity Foundation, the fundraising campaign for Mark CHEUNG Ho Yan has completed. The fund raised will be used to support the immunotherapy of Mark and 6 other patients who are suffered from the same disease. Thank you for all your kind-hearted support and generosity.
-------------------------------------------------------------------------------------
(2018/11/22)
This is an urgent appeal for your generosity to save the life of the 17-month-old son of Dr. CHEUNG Chun Kit, our medical alumnus of Class 2000.
Dr. Cheung Chun Kit is a CUHK medical graduate of Year 2000. His younger son, Cheung Ho Yan Mark, has recently been diagnosed to have Stage IV Neuroblastoma in November 2018, and is in an emergency need of donation to provide the necessary funding to support the life-saving yet expensive immunotherapy.
Mark was presented to his paediatrician for fever and cough in late October 2018. His cough resolved with treatment but his fever never completely went away. Two days prior to his diagnosis, Mark was more clingy than usual and did not like to walk. On a video clip, Mark was noted to have foot drop, a very significant red flag which may indicate a compression on the spinal cord. Emergency scans were immediately performed that night, and Mark was found to have a large tumour on the left side of his abdomen. The aggressive tumour had already spread silently to the back of his skull, his spine, his hips and had compressed his nerves which control his lower limbs, resulting in pain on standing and difficulty in walking. Mark is facing an imminent risk of paralysis.
Mark is diagnosed to have a rare childhood cancer which is called Stage IV neuroblastoma, a cancer which typically presents at late stage because it arises deep in the abdomen. To cure his aggressive cancer, Mark needs to survive through rounds of intensive chemotherapy, radiotherapy, surgery, bone marrow transplant, and finally, immunotherapy. The whole treatment duration lasts 1.5 to 2 years. To completely eradicate all cancer cells, immunotherapy will be needed to boost Mark’s survival from 20% to 50%. However, immunotherapy is a self-financed treatment in the public hospital and the treatment costs could be up to 2 million.
Such close encounter with death is not the first time for Mark. At the first week of life, Mark was diagnosed to have a rare heart problem called “Coarctation of Aorta”. Mark had received life-saving surgery to reestablish the blood flow across his aorta, the major blood vessel that allows blood to go from the heart to the brain and the rest of the body. In a report published in 2002, only 67 cases with dual heart condition and neuroblastoma were reported, giving an odd of 1 in 100 million for a child to be hit by these two rare diseases. Scientists have not yet completely understood the mechanisms that may cause the two conditions to appear in a single child.
It never rains but pours that Mark’s elder brother, now 5 years old, was diagnosed to have autism at around age 2. To enable the elder brother to have intensive training to improve his outcome and development, Mark’s mommy quit her job as a primary school teacher since the diagnosis of autism was made for his elder brother. Dr. Cheung, who is a medical doctor for the elderly, became the sole bread-winner of his family.
CUHK Medical Graduates of Year 2000 have initiated a fund-raising campaign for Mark and his family with the following two objectives:
1. To appeal for donation to support the costs of immunotherapy for Mark
2. To increase the public awareness on the grave needs of children with cancers
Enquiries:
CUHK Alumni Charity Foundation Limited
Email: info@cuhkacf.org
Telephone: 2180 4316
神經母細胞瘤第四期存活率 在 治療神經母細胞瘤新曙光! 可減緩腫瘤擴散-民視新聞 - YouTube 的推薦與評價
【民視即時新聞】 神經母細胞瘤 是一種好發於嬰幼兒時期的一種惡性腫瘤,在台灣每年約有30個病例,腫瘤轉移 存活率 只有30%,但過去都找不到有效治療方法 ... ... <看更多>
神經母細胞瘤第四期存活率 在 神經母細胞瘤2023-在Facebook/IG/Youtube上的焦點新聞和 ... 的推薦與評價
目前全國的兒童神經母細胞瘤標準治療,是由台灣兒童癌. 症研究群(TPOG)擬定的。近年來分子生物學的進步,可以. 檢測腫瘤細胞是否有MYCN基因異常放大,並 ... ... <看更多>
神經母細胞瘤第四期存活率 在 社團法人台灣神經母細胞瘤病友關懷協會 - Facebook 的推薦與評價
TAIWAN-HEALTHCARE.ORG ; 最難纏兒童癌/神經母細胞瘤免疫治療納暫時性給付| Healthcare+ B2B 全球醫療採購網 ; 神經母細胞瘤於兒童癌症死亡率高達15%, GD2抗體... ... <看更多>